Kerry Acocella, General Counsel and Secretary of Datadog, Inc. (NASDAQ:DDOG), filed a Form 4 on September 16, 2026, disclosing the sale of 5,280 shares of Class A Common Stock on September 14, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.
Christina Carvalho, Chief Accounting Officer of GXO Logistics, Inc., filed a Form 4 on September 16, 2026, reporting the acquisition of 21,309 Restricted Stock Units in GXO Logistics, Inc. common stock on September 14, 2026.
Andrew M. Seger, a director of German American Bancorp, Inc. (NASDAQ:GABC), filed a Form 4 on September 16, 2026, reporting the purchase of common stock through the company's Dividend Reinvestment and Stock Purchase Plan.
A Form 4 filed with the SEC on September 16, 2026, discloses that David Raymond Stewart, a director of AAON, Inc. (NASDAQ:AAON), purchased 1,000 shares of common stock on September 15, 2026, at a price of $74.66 per share.
Director Zachary W. Bawel filed a Form 4 with the SEC on September 16, 2026, disclosing a purchase of common stock in German American Bancorp, Inc. (NASDAQ:GABC) on September 15, 2026, through the company's Dividend Reinvestment and Stock Purchase Plan.
A Form 4 filed on September 16, 2026 reports that Christina M. Ryan, a director of German American Bancorp, Inc. (NASDAQ:GABC), acquired 124.2654 shares of common stock on September 15, 2026 through the company's Dividend Reinvestment and Stock Purchase Plan.
David Kirn, President and Chief Executive Officer of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT), filed a Form 4 on September 16, 2026, disclosing the sale of 58,333 shares of common stock on September 14, 2026.
John L. Brottem, General Counsel of Alamar Biosciences, Inc. (NASDAQ:ALMR), filed a Form 4 on September 16, 2026, reporting the acquisition of 29,000 restricted stock units and an employee stock option covering 85,000 shares of common stock, both transacted on September 14, 2026.
Johanna Mercier, Chief Commercial and Corporate Affairs Officer at Gilead Sciences, Inc. (NASDAQ:GILD), filed a Form 4 on September 16, 2026, disclosing the sale of 3,000 shares of common stock on September 15, 2026, pursuant to a Rule 10b5-1 trading plan.
Andrew D. Dickinson, Chief Financial Officer of Gilead Sciences, Inc., filed a Form 4 on September 16, 2026, reporting the sale of 3,000 shares of Gilead common stock on September 15, 2026.